IntoCell 2026 Q1: Continued Operating Loss, Disclosure Violation Penalty

Q1 2026 revenue: 0.28 billion KRW, operating loss: 3.53 billion KRW, net loss: 4.01 billion KRW (revenue increased YoY but losses continue)
Penalty of 612 million KRW imposed by Financial Services Commission for disclosure violation (April 20, 2026)
ITC-6146RO (B7-H3 ADC) Phase 1 clinical trial ongoing (IND approved in Korea and US, first patient dosed in March 2026)
Cash and cash equivalents: 8.62 billion KRW; borrowings: 10 billion KRW; debt ratio: 81.5%
Joint research agreement with Samsung Bioepis (up to 5 targets) continues; ABL Bio agreement terminated
R&D expenses: 3.08 billion KRW (1095% of revenue) - continued high R&D investment
No share buyback/cancellation or dividends